TMPRSS2 and COVID-19: Two of these molecules, camostat and nafamostat, were the most potent inhibitors of TMPRSS2 and are both in human clinical trials as an antiviral against COVID-19.19, 20 Another two drug repurposing candidates, otamixaban and PCI-27483, demonstrated activity but have not entered human clinical trials for treatment of COVID-19.